» Articles » PMID: 23372337

Report of Incidence and Mortality in China Cancer Registries, 2009

Overview
Specialty Oncology
Date 2013 Feb 2
PMID 23372337
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The National Central Cancer Registry (NCCR) collected cancer registration data in 2009 from local cancer registries in 2012, and analyzed to describe cancer incidence and mortality in China.

Methods: On basis of the criteria of data quality from NCCR, data submitted from 104 registries were checked and evaluated. There were 72 registries' data qualified and accepted for cancer registry annual report in 2012. Descriptive analysis included incidence and mortality stratified by area (urban/rural), sex, age group and cancer site. The top 10 common cancers in different groups, proportion and cumulative rates were also calculated. Chinese population census in 1982 and Segi's population were used for age-standardized incidence/mortality rates.

Results: All 72 cancer registries covered a total of 85,470,522 population (57,489,009 in urban and 27,981,513 in rural areas). The total new cancer incident cases and cancer deaths were 244,366 and 154,310, respectively. The morphology verified cases accounted for 67.23%, and 3.14% of incident cases only had information from death certifications. The crude incidence rate in Chinese cancer registration areas was 285.91/100,000 (males 317.97/100,000, females 253.09/100,000), age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 146.87/100,000 and 191.72/100,000 with the cumulative incidence rate (0-74 age years old) of 22.08%. The cancer incidence and ASIRC were 303.39/100,000 and 150.31/100,000 in urban areas whereas in rural areas, they were 249.98/100,000 and 139.68/100,000, respectively. The cancer mortality in Chinese cancer registration areas was 180.54/100,000 (224.20/100,000 in males and 135.85/100,000 in females), age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 85.06/100,000 and 115.65/100,000, and the cumulative incidence rate (0-74 age years old) was 12.94%. The cancer mortality and ASMRC were 181.86/100,000 and 80.86/100,000 in urban areas, whereas in rural areas, they were 177.83/100,000 and 94.40/100,000 respectively. Lung cancer, gastric cancer, colorectal cancer, liver cancer, esophageal cancer, pancreas cancer, encephaloma, lymphoma, female breast cancer and cervical cancer, were the most common cancers, accounting for 75% of all cancer cases in urban and rural areas. Lung cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, encephaloma, leukemia and lymphoma accounted for 80% of all cancer deaths. The cancer spectrum showed difference between urban and rural areas, males and females. The main cancers in rural areas were cancers of the stomach, followed by esophageal cancer, lung cancer, liver cancer and colorectal cancer, whereas the main cancer in urban areas was lung cancer, followed by liver cancer, gastric cancer and colorectal cancer.

Conclusions: The coverage of cancer registration population has been increasing and data quality is improving. As the basis of cancer control program, cancer registry plays an important role in making anti-cancer strategy in medium and long term. As cancer burdens are different between urban and rural areas in China, prevention and control should be implemented based on practical situation.

Citing Articles

Promoter methylation might shift the balance of Galectin-3 & 12 expression in adult acute myeloid leukemia patients.

Assem M, El-Araby R, Al-Karmalawy A, Nabil R, Kamal M, Belal A Front Genet. 2023; 14:1122864.

PMID: 36861129 PMC: 9968970. DOI: 10.3389/fgene.2023.1122864.


PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion.

Qiao D, Cheng J, Yan W, Li H Clin Transl Oncol. 2023; 25(8):2373-2383.

PMID: 36856921 PMC: 10293349. DOI: 10.1007/s12094-023-03120-w.


Urinary sp. Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway.

Zhang Y, Wang W, Zhou H, Cui Y Cancers (Basel). 2023; 15(3).

PMID: 36765767 PMC: 9913387. DOI: 10.3390/cancers15030809.


Recommendations for reducing exposure to medical X-ray irradiation (Review).

Shi H, Sun Z, Ju F Med Int (Lond). 2023; 2(4):22.

PMID: 36699506 PMC: 9829209. DOI: 10.3892/mi.2022.47.


Development and usability test of a symptom management WeChat Mini Program for parents of children with cancer.

Liu Y, Li D, Ruan H, Hu Y, Shen N Asia Pac J Oncol Nurs. 2022; 9(12):100166.

PMID: 36479577 PMC: 9720356. DOI: 10.1016/j.apjon.2022.100166.


References
1.
Zeng H, Zheng R, Zhang S, Zhao P, He J, Chen W . [Trend analysis of cancer mortality in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi. 2012; 34(7):525-31. DOI: 10.3760/cma.j.issn.0253-3766.2012.07.011. View

2.
Li G, Chen W . Representativeness of population-based cancer registration in China--comparison of urban and rural areas. Asian Pac J Cancer Prev. 2009; 10(4):559-64. View

3.
Parkin D . The evolution of the population-based cancer registry. Nat Rev Cancer. 2006; 6(8):603-12. DOI: 10.1038/nrc1948. View

4.
Chen W, Zheng R, Zeng H, Zhang S, Zhao P, He J . [Trend analysis and projection of cancer incidence in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi. 2012; 34(7):517-24. DOI: 10.3760/cma.j.issn.0253-3766.2012.07.010. View

5.
Larsen I, Smastuen M, Johannesen T, Langmark F, Parkin D, Bray F . Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2008; 45(7):1218-1231. DOI: 10.1016/j.ejca.2008.10.037. View